Figure 4.

Pharmacokinetics, neutralizing titers, and prophylactic efficacy of ADM03820 in a dose de-escalation study and IM antibody administration in NHPs

(A) Schema of study design. Different doses of ADM03820 were administered to cynomolgus macaques (day −6) by IM route (3.91, 1.95, 0.98, and 0.49 mg/kg; n = 3 NHP per group). One group of NHPs was left untreated (sham; n = 3) and served as a control. Animals in all groups were challenged with SARS-CoV-2 by the intranasal and intratracheal routes at day 0.

(B) Human antibody concentration was assessed by ELISA in serum at indicated time points after ADM03820 administration and viral challenge.

(C) Total neutralizing antibody titers in serum were assessed at indicated time points using a pseudovirus neutralization assay. The red line shows median titer of neutralizing antibodies in each group.

(D) sgRNA levels were assessed at various time points after viral challenge in BAL samples using qRT-PCR.

(E) sgRNA levels were assessed at various time points after viral challenge in NP swab samples. The red line depicts the median levels of sgRNA in each group. Each black curve shows measurements from an individual animal, with red lines indicating the median values of measurements for animals within each treatment group. Assay limit of detection = 50 copies/mL or 50 copies/swab. For statistical analysis, refer to STAR Methods section.